These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 20232070)

  • 1. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.
    Hu WT; Chen-Plotkin A; Arnold SE; Grossman M; Clark CM; Shaw LM; Pickering E; Kuhn M; Chen Y; McCluskey L; Elman L; Karlawish J; Hurtig HI; Siderowf A; Lee VM; Soares H; Trojanowski JQ
    Acta Neuropathol; 2010 Jun; 119(6):669-78. PubMed ID: 20232070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ
    Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
    Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ
    Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
    Paterson RW; Heywood WE; Heslegrave AJ; Magdalinou NK; Andreasson U; Sirka E; Bliss E; Slattery CF; Toombs J; Svensson J; Johansson P; Fox NC; Zetterberg H; Mills K; Schott JM
    Transl Psychiatry; 2016 Nov; 6(11):e952. PubMed ID: 27845782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
    Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
    Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
    Verhey FR; Visser PJ
    Ned Tijdschr Geneeskd; 2013; 157(11):A5596. PubMed ID: 23484512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.
    Craig-Schapiro R; Kuhn M; Xiong C; Pickering EH; Liu J; Misko TP; Perrin RJ; Bales KR; Soares H; Fagan AM; Holtzman DM
    PLoS One; 2011 Apr; 6(4):e18850. PubMed ID: 21526197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.
    Morenas-Rodríguez E; Cervera-Carles L; Vilaplana E; Alcolea D; Carmona-Iragui M; Dols-Icardo O; Ribosa-Nogué R; Muñoz-Llahuna L; Sala I; Belén Sánchez-Saudinós M; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2016; 50(2):539-46. PubMed ID: 26682689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.
    Roe CM; Fagan AM; Grant EA; Hassenstab J; Moulder KL; Maue Dreyfus D; Sutphen CL; Benzinger TL; Mintun MA; Holtzman DM; Morris JC
    Neurology; 2013 May; 80(19):1784-91. PubMed ID: 23576620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.